Clinical TrialMay 13, 2026, 09:32 AM
Polyrizon Secures First US Clinical Site for NASARIX™ Allergy Blocker Trial
AI Summary
Polyrizon Ltd. announced a significant step towards human clinical trials by securing its first U.S. clinical site for the NASARIX™ (PL-14) Allergy Blocker. The company signed a Clinical Trial Agreement (CTA) with a Texas-based research site specializing in allergy studies. This multi-center study will assess the safety, tolerability, and efficacy of the investigational intranasal spray in patients with seasonal allergic rhinitis, aligning with Polyrizon's broader regulatory strategy.
Key Highlights
- Polyrizon signed its first Clinical Trial Agreement (CTA) with a U.S. clinical research site.
- The site, located in Texas, specializes in allergy studies for the NASARIX™ (PL-14) Allergy Blocker.
- This marks a key milestone towards initiating the company's clinical program for NASARIX™.
- The multi-center study will evaluate the safety, tolerability, and efficacy of the Allergy Blocker.
- The trial focuses on patients with seasonal allergic rhinitis.
- NASARIX™ is an investigational intranasal formulation designed as a non-pharmacological barrier against allergens.
- Additional clinical sites are expected to be added in the coming months for the multi-center trial.
Price Impact
More from PLRZ